Logo image of PATH

UIPATH INC - CLASS A (PATH) Stock Fundamental Analysis

NYSE:PATH - New York Stock Exchange, Inc. - US90364P1057 - Common Stock - Currency: USD

12.705  +0.12 (+0.91%)

Fundamental Rating

5

PATH gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 282 industry peers in the Software industry. While PATH has a great health rating, there are worries on its profitability. PATH has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

PATH had positive earnings in the past year.
PATH had a positive operating cash flow in the past year.
In the past 5 years PATH always reported negative net income.
In multiple years PATH reported negative operating cash flow during the last 5 years.
PATH Yearly Net Income VS EBIT VS OCF VS FCFPATH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

PATH has a Return On Assets of -2.55%. This is comparable to the rest of the industry: PATH outperforms 57.45% of its industry peers.
PATH has a better Return On Equity (-3.97%) than 60.99% of its industry peers.
Industry RankSector Rank
ROA -2.55%
ROE -3.97%
ROIC N/A
ROA(3y)-5.87%
ROA(5y)-9.74%
ROE(3y)-8.52%
ROE(5y)-15%
ROIC(3y)N/A
ROIC(5y)N/A
PATH Yearly ROA, ROE, ROICPATH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

Looking at the Gross Margin, with a value of 82.62%, PATH belongs to the top of the industry, outperforming 90.43% of the companies in the same industry.
PATH's Gross Margin has been stable in the last couple of years.
PATH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.08%
PATH Yearly Profit, Operating, Gross MarginsPATH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

PATH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PATH has been reduced compared to 1 year ago.
Compared to 5 years ago, PATH has more shares outstanding
PATH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PATH Yearly Shares OutstandingPATH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
PATH Yearly Total Debt VS Total AssetsPATH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

An Altman-Z score of 4.26 indicates that PATH is not in any danger for bankruptcy at the moment.
PATH has a better Altman-Z score (4.26) than 65.25% of its industry peers.
There is no outstanding debt for PATH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.26
ROIC/WACCN/A
WACC11.11%
PATH Yearly LT Debt VS Equity VS FCFPATH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 2.95 indicates that PATH has no problem at all paying its short term obligations.
PATH's Current ratio of 2.95 is fine compared to the rest of the industry. PATH outperforms 76.95% of its industry peers.
PATH has a Quick Ratio of 2.95. This indicates that PATH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PATH (2.95) is better than 78.01% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.95
PATH Yearly Current Assets VS Current LiabilitesPATH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

6

3. Growth

3.1 Past

PATH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.14%.
The Earnings Per Share has been growing by 88.99% on average over the past years. This is a very strong growth
PATH shows a small growth in Revenue. In the last year, the Revenue has grown by 7.21%.
Measured over the past years, PATH shows a very strong growth in Revenue. The Revenue has been growing by 33.58% on average per year.
EPS 1Y (TTM)-7.14%
EPS 3Y88.99%
EPS 5YN/A
EPS Q2Q%-15.38%
Revenue 1Y (TTM)7.21%
Revenue growth 3Y17.01%
Revenue growth 5Y33.58%
Sales Q2Q%6.42%

3.2 Future

PATH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.84% yearly.
Based on estimates for the next years, PATH will show a quite strong growth in Revenue. The Revenue will grow by 11.61% on average per year.
EPS Next Y2.63%
EPS Next 2Y7.69%
EPS Next 3Y8.79%
EPS Next 5Y1.84%
Revenue Next Year8.42%
Revenue Next 2Y8.38%
Revenue Next 3Y8.77%
Revenue Next 5Y11.61%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PATH Yearly Revenue VS EstimatesPATH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B 2B 2.5B
PATH Yearly EPS VS EstimatesPATH Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0.2 0.4 0.6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

PATH is valuated rather expensively with a Price/Earnings ratio of 24.43.
Based on the Price/Earnings ratio, PATH is valued a bit cheaper than the industry average as 75.53% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.54. PATH is around the same levels.
The Price/Forward Earnings ratio is 20.29, which indicates a rather expensive current valuation of PATH.
78.01% of the companies in the same industry are more expensive than PATH, based on the Price/Forward Earnings ratio.
PATH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 36.44.
Industry RankSector Rank
PE 24.43
Fwd PE 20.29
PATH Price Earnings VS Forward Price EarningsPATH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, PATH is valued cheaply inside the industry as 80.14% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 21.72
EV/EBITDA N/A
PATH Per share dataPATH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)9.3
PEG (5Y)N/A
EPS Next 2Y7.69%
EPS Next 3Y8.79%

More info and screens

0

5. Dividend

5.1 Amount

PATH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UIPATH INC - CLASS A

NYSE:PATH (7/21/2025, 10:13:02 AM)

12.705

+0.12 (+0.91%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)05-29 2025-05-29/amc
Earnings (Next)09-03 2025-09-03/amc
Inst Owners72.77%
Inst Owner Change0.02%
Ins Owners8.35%
Ins Owner Change0.25%
Market Cap6.80B
Analysts66
Price Target14.23 (12%)
Short Float %14.06%
Short Ratio5.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.23%
Min EPS beat(2)7.36%
Max EPS beat(2)27.1%
EPS beat(4)4
Avg EPS beat(4)25.4%
Min EPS beat(4)7.36%
Max EPS beat(4)47.41%
EPS beat(8)8
Avg EPS beat(8)46.66%
EPS beat(12)12
Avg EPS beat(12)102.69%
EPS beat(16)16
Avg EPS beat(16)98.69%
Revenue beat(2)1
Avg Revenue beat(2)1.34%
Min Revenue beat(2)-2.36%
Max Revenue beat(2)5.03%
Revenue beat(4)3
Avg Revenue beat(4)1.19%
Min Revenue beat(4)-2.36%
Max Revenue beat(4)5.03%
Revenue beat(8)5
Avg Revenue beat(8)1%
Revenue beat(12)9
Avg Revenue beat(12)2.32%
Revenue beat(16)13
Avg Revenue beat(16)2.65%
PT rev (1m)2.06%
PT rev (3m)13.73%
EPS NQ rev (1m)-2.03%
EPS NQ rev (3m)23.36%
EPS NY rev (1m)-0.7%
EPS NY rev (3m)0.77%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)4.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.6%
Valuation
Industry RankSector Rank
PE 24.43
Fwd PE 20.29
P/S 4.68
P/FCF 21.72
P/OCF 20.02
P/B 4
P/tB 4.38
EV/EBITDA N/A
EPS(TTM)0.52
EY4.09%
EPS(NY)0.63
Fwd EY4.93%
FCF(TTM)0.59
FCFY4.6%
OCF(TTM)0.63
OCFY4.99%
SpS2.71
BVpS3.17
TBVpS2.9
PEG (NY)9.3
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.55%
ROE -3.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.62%
FCFM 21.57%
ROA(3y)-5.87%
ROA(5y)-9.74%
ROE(3y)-8.52%
ROE(5y)-15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.08%
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 170.17%
Cap/Sales 1.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 2.95
Altman-Z 4.26
F-Score6
WACC11.11%
ROIC/WACCN/A
Cap/Depr(3y)82.11%
Cap/Depr(5y)72.19%
Cap/Sales(3y)1.29%
Cap/Sales(5y)1.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.14%
EPS 3Y88.99%
EPS 5YN/A
EPS Q2Q%-15.38%
EPS Next Y2.63%
EPS Next 2Y7.69%
EPS Next 3Y8.79%
EPS Next 5Y1.84%
Revenue 1Y (TTM)7.21%
Revenue growth 3Y17.01%
Revenue growth 5Y33.58%
Sales Q2Q%6.42%
Revenue Next Year8.42%
Revenue Next 2Y8.38%
Revenue Next 3Y8.77%
Revenue Next 5Y11.61%
EBIT growth 1Y38.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.08%
EBIT Next 3Y26.34%
EBIT Next 5Y22.63%
FCF growth 1Y232.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y208.1%
OCF growth 3YN/A
OCF growth 5YN/A